WO1996000571A1 - Agent antibacterien - Google Patents
Agent antibacterien Download PDFInfo
- Publication number
- WO1996000571A1 WO1996000571A1 PCT/JP1995/001290 JP9501290W WO9600571A1 WO 1996000571 A1 WO1996000571 A1 WO 1996000571A1 JP 9501290 W JP9501290 W JP 9501290W WO 9600571 A1 WO9600571 A1 WO 9600571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- unsubstituted
- halogen atom
- antibacterial agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
- C07C255/21—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton the carbon skeleton being further substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present invention relates to an antibacterial agent used for preventing or treating infectious diseases of animals such as human and domestic animals. According to the present invention, an antibacterial agent having antibacterial activity against Gram-negative bacteria and Gram-positive bacteria can be provided. Background art
- MRSA methicillin-resistant Staphylococcus aureus
- the present invention solves the above problems and provides an antibacterial agent having high antibacterial activity against gram-negative bacteria, gram-positive bacteria, and gram-positive bacteria such as staphylococci that have become drug-resistant.
- the purpose is to:
- ketonitrile derivatives which have been recognized as having herbicidal activity (JP-A-5-148213, JP-A-6-179664) And Japanese Patent Application Laid-open No. 7-109492), and also a ketonitrile derivative having no herbicidal activity, has been found to have antibacterial activity, and it has been found that gram-positive bacteria such as staphylococci and streptococci and gram They have found that they exhibit high antibacterial activity against negative bacteria, and have completed the present invention. Disclosure of the invention
- the present invention provides the following general formula (1)
- R 1 represents a hydrogen atom or a lower alkyl group
- R 2 , R 3 , R 4 and R 5 are the same or different and are a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower alkoxyl group Or a substituted or unsubstituted phenoxy group
- X represents a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group
- Y is a substituted or unsubstituted aromatic hydrocarbon group.
- a substituted or unsubstituted heterocyclic group a carbonyl group substituted with a substituted or unsubstituted aromatic hydrocarbon group, a carbonyl group substituted with a substituted or unsubstituted heterocyclic group, or an N, N-disubstituted rubamoyl group
- the present invention relates to an animal antibacterial agent containing a ketonitrile derivative represented by or a salt thereof as an active ingredient.
- examples of the lower alkyl group represented by R 1 include a methyl group, an ethyl group, a propyl group, and an isopropyl group, and R ′ is particularly preferably a hydrogen atom or a methyl group. .
- R 2 to R 5 represent a hydrogen atom; a halogen atom such as chlorine, bromine, fluorine and iodine; a nitro group; a lower alkyl group such as a methyl group, an ethyl group, a propyl group and a butyl group.
- a lower alkoxyl group such as a methoxy group, an ethoxy group, and a propoxy group; and a phenoxy group such as a 2-chloro-4-1-trifluoromethylphenoxy group.
- examples of the unsubstituted aromatic hydrocarbon group represented by X include a phenyl group and a naphthyl group.
- an unsubstituted heterocyclic group a 5-membered ring containing at least one hetero atom such as an oxygen atom, a zeo atom or a nitrogen atom or Groups consisting of 6-membered rings or groups formed by condensing them with a benzene ring, for example, pyridyl, quinolyl, isoquinolyl, pyrimidinyl, oxazolyl, benzoxazolyl, furyl, benzofuryl
- An aromatic heterocyclic group such as a thiazolyl group, a benzothiazolyl group, a phenyl group, a phenyl group, a benzothienyl group; a non-aromatic heterocyclic group such as a piperidyl group, a pyrrolidinyl
- these substituents include a halogen atom such as chlorine, fluorine, bromine, and iodine; a haloalkyl group such as trifluoromethyl group; a nitro group; a cyano group; Examples thereof include an alkyl group, an alkylthio group, and an alkoxycarbonyl group.
- a halogen atom such as chlorine, fluorine, bromine, and iodine
- a haloalkyl group such as trifluoromethyl group
- a nitro group such as a cyano group
- alkyl group such as an alkylthio group
- alkoxycarbonyl group examples thereof include an alkyl group, an alkylthio group, and an alkoxycarbonyl group.
- compounds substituted by one or two of the same or different species selected from a halogen atom and a haloalkyl group are preferable because they exhibit higher antibacterial activity.
- examples of the unsubstituted aromatic hydrocarbon group represented by Y include a phenyl group and a naphthyl group.
- the unsubstituted heterocyclic group a group consisting of a 5- or 6-membered ring containing at least one heteroatom such as an oxygen atom, a zeolite atom or a nitrogen atom, or a group condensed with a benzene ring Examples of such a group include the heterocyclic groups exemplified in the section of the group X, and an aromatic heterocyclic group is particularly preferable.
- these substituents include halogen atoms such as chlorine, fluorine, bromine, and iodine; Examples thereof include a haloalkyl group such as a methyl group, an alkyl group, an alkoxy group, an alkylthio group, and an alkoxycarbonyl group.
- the N, N-disubstituted rubamoyl group includes a substituted or unsubstituted alkyl group, alkenyl group, alkoxyl group, substituted or unsubstituted aromatic group, and substituted or unsubstituted heterocyclic group.
- two substituents bonded to carbamoyl groups may combine to form a heteroatom-containing ring (eg, a pyrrolidine ring, a piperidine ring, a morpholine ring) May be condensed with a benzene ring or substituted with an alkyl group. And an azacycloalkylcarbonyl group.
- a heteroatom-containing ring eg, a pyrrolidine ring, a piperidine ring, a morpholine ring
- the compound of the above general formula (1) is roughly classified into the following three general formulas (2), (3) and (4) according to the form of the substituent on the benzene ring. Any of these compounds can be used.
- X represents a substituted or unsubstituted phenyl group
- a substituted or unsubstituted pyridyl group, a substituted or unsubstituted benzoxazolyl group, and a substituted or unsubstituted benzothiazolyl group are preferred.
- a phenyl group optionally substituted with a halogen atom, a haloalkyl group or a cyano group
- a pyridyl group optionally substituted with a halogen atom, a haloalkyl group or a cyano group
- Y is a substituted or unsubstituted phenyl group, a substituted or unsubstituted A pyrimidinyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, or an N, N-disubstituted rubamoyl group is preferred.
- a phenyl group optionally substituted with a halogen atom, a haloalkyl group, an alkyl group or an alkoxyl group; a pyrimidinyl group optionally substituted with a halogen atom, a haloalkyl group, an alkyl group or an alkoxyl group; A phenyl group optionally substituted by a haloalkyl group, an alkyl group or an alkoxyl group; a naphthyl group optionally substituted by a halogen atom, a haloalkyl group, an alkyl group or an alkoxyl group; a lower alkyl group, an aryl group or an aralkyl group An N, N-disubstituted rubamoyl group substituted with a 1-azacycloalkylcarbonyl group which may be condensed with a benzene ring or substituted with an alkyl group.
- X and Y are preferably a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted aromatic heterocyclic group, and in particular, X is a substituted or unsubstituted fluorinated group.
- X is a phenyl group optionally substituted by a halogen atom, a haloalkyl group or a cyano group; a pyridyl group optionally substituted by a halogen atom, a haloalkyl group or a cyano group; a halogen atom, a haloalkyl group or a cyano group.
- halogen atom A naphthyl group optionally substituted with a haloalkyl group, an alkyl group or an alkoxyl group; an N, N-disubstituted rubamoyl group substituted with a lower alkyl group, an aryl group or an aralkyl group; May be substituted with an alkyl group 1 Those which are monoazacycloalkylcarbonyl groups are preferred.
- X is a substituted or unsubstituted pyridyl group
- Y is a substituted or unsubstituted phenyl group, a substituted or unsubstituted pyrimidinyl group, or N
- X is a substituted or unsubstituted phenyl group
- Y is a substituted or unsubstituted pyrimidinyl group or an N, N-disubstituted rubamoyl group
- X is substituted Or, an unsubstituted benzoxazolyl group or a substituted or unsubstituted benzothiazolyl group, wherein Y is a substituted or unsubstituted phenyl group is more preferable.
- ketonitrile derivatives represented by the general formula (2) 4-1 [4- (3-chloro-5-trifluoromethyl-2-pyridylloquine) phenoxy] -12- (3,4-dichloromouth phenyl) 1-3-oxopentanonitrile (Compound No. 4) is preferred because of its particularly high antibacterial activity.
- X is preferably a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group, particularly a substituted or unsubstituted fuunyl group or a substituted or unsubstituted pyridyl group. And a phenyl group substituted with a halogen atom or a haloalkyl group, and a pyridyl group substituted with a halogen atom or a haloalkyl group.
- Y is preferably a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, a substituted or unsubstituted pyridyl group, or a N, N-disubstituted rubamoyl group, particularly halogen.
- a phenyl group optionally substituted with an atom, a haloalkyl group or an alkoxyl group or a N, N-disubstituted rubamoyl group is preferable, and a phenyl group further substituted with a halogen atom or a haloalkyl group is preferable.
- X is a substituted phenyl group or a substituted pyridyl group
- Y is a substituted or unsubstituted phenyl group, a substituted or unsubstituted pyridyl group or an N, N-disubstituted rubamoyl group
- X is preferably a phenyl group substituted with a halogen atom or a haloalkyl group or a pyridyl group substituted with a halogen atom or a haloalkyl group
- Y may be substituted with a halogen atom, a haloalkyl group or an alkoxyl group.
- ketonitrile derivatives represented by the general formula (3) 2- (3-bromophenenyl) 141 [2-chloro-5- (2-chloro-1-414-trifluoromethylphenoxy) phenoxy] 13- Oxopentanonitrile, 4- [3- (2-chloro-4-1trifluoromethylphenoxy) phenoxy] -1 2- (3,4-dichlorophenyl) 13-oxopentanonitrile, 4- [3— (2-Chloro-4-trifluoromethylphenoxy) -15-methylphenoxy] -12- (3,4-dichlorophenyl) -13-oxopentanonitrile is preferred because of its particularly high antibacterial activity.
- X is preferably a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group, particularly a substituted or unsubstituted phenyl group, or a substituted or unsubstituted group.
- Y is preferably a substituted or unsubstituted phenyl group, a substituted or unsubstituted naphthyl group, or a substituted or unsubstituted pyridyl group, particularly substituted with a halogen atom, a haloalkyl group or an alkoxyl group.
- An optionally substituted phenyl group is preferred, and a phenyl group further substituted with a halogen atom or a haloalkyl group is preferred.
- X is preferably a substituted phenyl group or a substituted pyridyl group
- Y is preferably a substituted or unsubstituted phenyl group, or a substituted or unsubstituted pyridyl group.
- X is a halogen atom or Preferred is a phenyl group substituted with a haloalkyl group or a pyridyl group substituted with a halogen atom or a haloalkyl group
- Y is a phenyl group or a phenyl group substituted with a halogen atom, a haloalkyl group or an alkoxyl group.
- ketonitrile derivatives represented by the general formula (4) among the four, [2- (2- (chloro-1,4-trifluoromethylphenoxy) -1,4-methylphenoxy] —2 -— ( 3,4-dichloromouth phenyl) 1-3-oxopentanonitrile, 4- [21- (2-chloro- 4-trifluoromethylphenoxy) 1-5-methylphenoxy] 1- 2- (3,4-dichlorophenyl) 1-3-oxopentanonitrile, 4- [2- (2-chloro-1-41-trifluoromethylphenoxy) 1-4-methylphenoxy] — 2— (3-bromophenyl) -1-3-oxopentanonitrile and 4- [2- (2-chloro-4-1-trifluoromethylphenoxy) -1 5-methylphenoxy] 1 2- (3-promophenyl) -1 3-oxopentanonitrile is preferred because of its particularly high antibacterial activity.
- the ketonitrile derivative (1) used in the present invention may be a salt thereof.
- a salt include salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid, and the like; acetic acid, fumaric acid, Salts with organic acids such as maleic acid, lactic acid, tartaric acid, citric acid, malic acid, oxalic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid; acidic amino acids such as aspartic acid and glutamic acid Metal salts such as sodium, potassium, calcium, magnesium, zinc, and silver; salts with organic bases such as dimethylamine, triethylamine, diethanolamine, and benzylamine; with basic amino acids such as lysine and arginine Salts and the like can be mentioned.
- a solvate represented by a hydrate of the ketonitrile derivative (1) can also be mentioned.
- ketonitrile derivative (1) used in the present invention can be produced, for example, according to the following production methods (a) to (e).
- M represents a hydrogen atom or an alkali metal
- Z represents a halogen atom
- R 1 , R 2 , R 3 , R 4 , R 5 , X and Y have the same meanings as described above.
- R 6 represents an alkoxyl group or a halogen atom, and R], R 2 , R 3 , R 4 , R 5 , X and Y have the same meanings as described above.
- Y ′ and Y ⁇ are each a hydrogen atom, a substituted or unsubstituted alkyl group, an alkenyl group, an alkoxyl group, an alkylthio group, an alkoxycarbonyl group, a cyano group, a substituted or unsubstituted aromatic group, Or a substituted or unsubstituted heterocyclic group, wherein Y ′ and ⁇ may be bonded to each other to form a saturated or unsaturated ring which may contain a hetero atom; R 1 , R 2 , R 3 , R 4 , R 5 , X, ⁇ and ⁇ have the same meanings as above.)
- the reaction solvent used in the above reactions (a) to (e) is not particularly limited, and a known solvent can be used. Typical examples that are generally preferably used include alcohols such as methanol and ethanol; ethers such as getyl ether, dimethyloxetane, tetrahydrofuran, and dioxane; and aromatic hydrocarbons such as benzene and toluene. Chlorinated solvents such as methylene chloride, chloroform, carbon tetrachloride, etc .; N, N-dimethylformamide, dimethylsulfoxide, sulfolane, etc.
- a hydrogen halide scavenger coexists in order to trap hydrogen
- the hydrogen halide scavenger is not particularly limited, and a known one can be used.
- Representative examples of preferably used hydrogen halide scavengers include trialkylamines such as triethylamine, trimethylamine, and tripropylamine; pyridine, sodium alcohol, and potassium. Examples include alcoholate, DBU, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride and the like.
- the reactions (a) to (e) are preferably carried out at 130 to 200 ° C., particularly preferably at 5 to 150 ° C., and the reaction time is 0.5 to 45 hours, especially 3 to 50 hours. ⁇ 24 hours is preferred.
- the method for isolating and purifying the ketonitrile derivative (1) from the reaction mixture is not particularly limited, and a known method can be employed. Usually, a method is preferably used in which the reaction solution is added to water, extracted with an organic solvent, the solvent is removed, and the residue is recrystallized or purified by column chromatography.
- the ketonitrile derivative used in the present invention is generally a pale yellow or yellowish brown viscous substance or solid at normal temperature and normal pressure.
- the dosage form and administration method of the antibacterial agent of the present invention can be appropriately selected according to the administration target of animals, for example, mammals including humans, poultry, fish and the like.
- a pharmaceutically acceptable pharmaceutical carrier such as a filler, a bulking agent, a binder, a disintegrant, a dissolution promoter, a wetting agent, an excipient, or a lubricant is used.
- a pharmaceutically acceptable pharmaceutical carrier such as a filler, a bulking agent, a binder, a disintegrant, a dissolution promoter, a wetting agent, an excipient, or a lubricant is used.
- a pharmaceutically acceptable pharmaceutical carrier such as a filler, a bulking agent, a binder, a disintegrant, a dissolution promoter, a wetting agent, an excipient, or a lubricant is used.
- a stabilizer, a preservative, a tonicity agent, a solubilizing agent, and the like can be added to the preparation. Also, after storing the injection solution in a storage container, the solution is freeze-dried and solidified to prepare an injection preparation for use. Furthermore, one dose can be stored in one container, and multiple doses can be stored in one container.
- a suspending agent, an emulsifier and the like can be added.
- a method of orally administering directly or mixed or dissolved in feed or drinking water, injection, rectal administration, intramammary Parenteral administration by administration, drug bath (used in the case of fish), etc. can be used.
- these administration methods e.g. powders, fine granules Preparations, dissolvable powders, syrups, solutions, injections, suppositories, breast injections and the like.
- the dose of the antibacterial agent of the present invention when administered to a human, is from 5 Omg to 1 g, preferably from 10 Omg to 60 Omg per adult per day.
- the dose is lmg to 20OmgZ / kg body weight / day, preferably 5mg to 10Omg / day, administered once to 2 to 4 times a day.
- the daily dose can be adjusted appropriately according to the symptoms, age, weight of the body, and the like.
- the antibacterial agent of the present invention has a high antibacterial property against bacteria such as Staphylococcus, Streptococcus, Listeria, Bacillus, Clostridium, Corynebacterium, Erythroidrox, Bordetella, and Pasteurella. Have activity.
- the antibacterial agent of the present invention may be used for various diseases caused by these bacteria, for example, folliculitis, sclerosis, erysipelas, lymphatic (node) inflammation, subcutaneous abscess, sweat glanditis, perianal abscess, mastitis , Trauma, burns, superficial secondary infections such as surgical wounds, bronchitis, pneumonia, nephritis, cystitis, urethritis, intrauterine infection, otitis media, sinusitis, endocarditis, sepsis Applicable to anthrax, tetanus, etc.
- Production Example 4 Compound numbers 1 to 47 were produced in the same manner as in Production Examples 1 to 3.
- Lithium diisopropylamide (2 M, heptane / THF / ethylbenzene solution) 3 was dissolved in tetrahydrofuran (THF) 1, and a THF solution of 0.7 g of phenylacetonitrile was added dropwise at room temperature. Further, a solution of 2 g of methyl 2- [3- (2-chloro-4- trifluoromethylphenoxy) phenoxy] propionate in THF was added dropwise, and the mixture was stirred at room temperature for 6 hours. Add ether 15 and add dilute hydrochloric acid, The extract was washed successively with water and saturated saline, and dried over anhydrous magnesium sulfate.
- Compound Nos. 303 and 304 are mixtures of R 2 having a chlorine atom substitution position of 4 or 5 c
- Compound No. 305 is a mixture of R 2 having a t-butyl substitution position of 4 or 5 is there.
- Compound Nos. 308 and 309 are mixtures of R 2 having a methyl group substitution position of 4 or 5
- Compound No. 310 is a mixture of R 2 having a t-butyl group substitution position of 4 or 5) is there.
- a suspension of the compound suspended in a 0.5% CMC aqueous solution in a mouse of 5 mice per group was administered to a final dose of 707, 100, 140, or 200 OmgZkg.
- the test was carried out by gavage once by gavage and observation for 14 days.
- the LD 50 value was 200 Omg / kg or more by oral administration, indicating that the compound was highly safe.
- sample stock solution was dissolved in dimethyl sulfoxide (DMSO), and diluted with an equal volume of sterilized distilled water to prepare a 100 g sample stock solution.
- DMSO dimethyl sulfoxide
- the sample stock solution was poured into the first well of the series and serially diluted 10-fold. Then, as the final inoculum volume was prepared overnight cultured test bacteria liquid is at 37 in advance the broth (Staphylococcus aureus Staphylococcus aureus 209- P) becomes 1 0 6 CFUZ, each Uweru Inoculated.
- Final sample concentrations were 100, 10 and 1 gZ.
- the antibacterial activity was evaluated by inhibiting the growth of the bacteria (determined by the turbidity of the medium) after culturing at 37 ° C for 18 hours (inhibitory concentration, hereinafter abbreviated as IC).
- IC inhibitor concentration
- ⁇ 100 means 100 ⁇ g / ⁇ 10 indicates that the growth of the bacteria is inhibited below 10 g / m, and ⁇ ⁇ 1 '' indicates that the growth of the bacteria is inhibited below 1 IgZm. (The same applies to the following examples).
- the antibacterial activity was measured in the same manner as in Example 4. However, as the test microorganism, Staphylococcus aureus TI-11 strain was used. The results are shown in Table 40.
- DMSO dimethyl sulfoxide
- DI FCO Mueller Hinton Broth
- the antibacterial effect was determined after culturing at 37 ° C for 18 hours, and evaluated by the IC value in the same manner as in Example 4. The results are shown in Table 43.
- MIC Minimum inhibitory concentration
- Antimicrobial activity MIC (g / i) derived from the test strain S. phylococcus aureus 209 P Standard strain 1.56 S. phylococcus aureus T 1-1 cattle 6.25 S. phyllococcus paleus 3-2 Pig 3. Staphylococcus apereus 1 SS 1 3.13 Pasulella haemolytica IF-1 5 cattle 6.2.5 Pasulella maltosida IF-1 7 cattle 1.56 6 As is evident from Table 44, the MIC value of compound 4 is 1 It was 0.56 to 6.25 xzg /, indicating high antibacterial activity against each test bacterium.
- Compound 4 showed high activity against pathogenic gram-positive bacteria including methicillin-resistant staphylococci, and was particularly effective against methicillin-resistant staphylococcus aureus.
- the components of the following formulation were filled in a force capsule in a conventional manner to obtain a force capsule.
- the final dose of the compound suspension in 0.5% CMC aqueous solution was 50,000, 100,000, 150,000 or 200,000 mg / kg in 5 mice per group.
- the test was performed by gavage once and observed for 14 days. As a result, LD 5 for mice of both specimens. The values were all higher than 200 Omg / kg, which proved to be highly safe compounds.
- ketonitrile derivatives of Compound Nos. 103 and 155 were orally administered to mice at 10 Omg / kg body weight to conduct an absorption test.
- the serum was separated from the blood collected 1, 3, 5 and 24 hours after the compound administration, and the concentration of the compound in the serum was measured by the HPLC method.As a result, Compound No. Peaked after 3 hours, and both were found to be rapidly absorbed by oral administration.
- the antibacterial activity was measured in the same manner as in Example 8 using a ketonitrile derivative having the compound number shown in Table 48 as a specimen. However, Staphylococcus aureus 209-P was used as the test bacterium. The results are shown in Table 48. Table 48
- the antibacterial activity was measured in the same manner as in Example 8. However, as a test bacterium, Staphylococcus aureus TI-11 strain was used. The results are shown in Table 49.
- the antibacterial activity was measured in the same manner as in Example 8. However, as a test bacterium, Pasteurella multocida (Paseurella multocida) was used. The results are shown in Table 50.
- the antibacterial activity was measured in the same manner as in Example 8. However, as test bacteria, Bordetella bronxeptica (S1 strain) and Bordetella bronxeptica (SM2-4 strain) were used. The results are shown in Table 51. Table 5 1
- the antimicrobial activity against enterococci and pastella bacteria derived from fish was measured in the same manner as in Example 8 using ketonitrile derivatives having the compound numbers shown in Tables 53 to 55 as specimens. However, 1.5% of sodium chloride was added to the medium, and the culture temperature was 25 ° C. The results are shown in Tables 53 to 55.
- Pasulella pisisida KP94-05 ⁇ 10 ⁇ 100 ⁇ 100 ⁇ 10 ⁇ 100 ⁇ 100 ⁇ 100 ⁇ 100 ⁇ 10 ⁇ 10
- the antibacterial agent of the present invention has high antibacterial activity against Gram-positive bacteria and Gram-negative bacteria, and particularly has high antibacterial activity against pathogenic staphylococci including methicillin-resistant Staphylococcus aureus (MRSA). are doing. Therefore, the antibacterial agent of the present invention can be used as a prophylactic or therapeutic agent for various infectious diseases in humans and non-human mammals, poultry, fish and the like caused by Gram-positive bacteria and Gram-negative bacteria.
- MRSA methicillin-resistant Staphylococcus aureus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95923538A EP0768085A1 (en) | 1994-06-29 | 1995-06-28 | Antibacterial agent |
JP50402397A JP3670292B2 (ja) | 1995-06-28 | 1995-12-28 | ケトニトリル誘導体及びこれを含有する抗菌剤及び医薬 |
PCT/JP1995/002751 WO1997001532A1 (fr) | 1995-06-28 | 1995-12-28 | Derives cetonitrile, agent antibacterien et medicament contenant ces derives |
CA002224275A CA2224275A1 (en) | 1995-06-28 | 1995-12-28 | Ketonitrile derivatives, and antibacterial agents and drugs containing the same |
DE69521347T DE69521347T2 (de) | 1995-06-28 | 1995-12-28 | Ketonitrilderivate, antibaktrielle mittel und sie enthaltende arzneimittel |
US08/973,715 US5968977A (en) | 1995-06-28 | 1995-12-28 | Ketonitrile derivatives and antibacterial agent and drugs containing the same |
EP95942305A EP0863132B1 (en) | 1995-06-28 | 1995-12-28 | Ketonitrile derivatives and antibacterial agent and drug containing the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/147466 | 1994-06-29 | ||
JP14746694 | 1994-06-29 | ||
JP8261595 | 1995-04-07 | ||
JP7/82615 | 1995-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996000571A1 true WO1996000571A1 (fr) | 1996-01-11 |
Family
ID=26423643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/001290 WO1996000571A1 (fr) | 1994-06-29 | 1995-06-28 | Agent antibacterien |
PCT/JP1995/001289 WO1996000570A1 (fr) | 1994-06-29 | 1995-06-28 | Agent antibacterien |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/001289 WO1996000570A1 (fr) | 1994-06-29 | 1995-06-28 | Agent antibacterien |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0768085A1 (ja) |
JP (1) | JP3650166B2 (ja) |
KR (1) | KR970703764A (ja) |
CN (1) | CN1151696A (ja) |
AU (1) | AU2806495A (ja) |
CA (1) | CA2193865A1 (ja) |
FI (1) | FI965230A (ja) |
MX (1) | MX9700045A (ja) |
NO (1) | NO965605L (ja) |
WO (2) | WO1996000571A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0863132B1 (en) * | 1995-06-28 | 2001-06-13 | Tokuyama Corporation | Ketonitrile derivatives and antibacterial agent and drug containing the same |
JP4607419B2 (ja) * | 2002-11-14 | 2011-01-05 | 日本エンバイロケミカルズ株式会社 | キノキサリン系化合物またはその塩、および、工業用殺菌組成物 |
CN115368252B (zh) * | 2022-09-19 | 2024-01-12 | 西北农林科技大学 | 一种4-胺基酚类衍生物及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05339224A (ja) * | 1992-06-10 | 1993-12-21 | Tokuyama Soda Co Ltd | シアノケトン誘導体の製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3313941A1 (de) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | 4-azolyl-pentannitrile, verfahren zur herstellung dieser verbundungen sowie diese enthaltende biozide mittel |
EP0506373B1 (en) * | 1991-03-29 | 1995-11-29 | Tokuyama Corporation | Cyanoketone derivative and herbicide containing it as an active component |
JP3228612B2 (ja) * | 1993-10-08 | 2001-11-12 | 株式会社トクヤマ | シアノケトン誘導体 |
-
1995
- 1995-06-28 WO PCT/JP1995/001290 patent/WO1996000571A1/ja not_active Application Discontinuation
- 1995-06-28 AU AU28064/95A patent/AU2806495A/en not_active Abandoned
- 1995-06-28 MX MX9700045A patent/MX9700045A/es unknown
- 1995-06-28 EP EP95923538A patent/EP0768085A1/en not_active Withdrawn
- 1995-06-28 CA CA002193865A patent/CA2193865A1/en not_active Abandoned
- 1995-06-28 WO PCT/JP1995/001289 patent/WO1996000570A1/ja not_active Application Discontinuation
- 1995-06-28 EP EP95923537A patent/EP0761215A4/en not_active Withdrawn
- 1995-06-28 JP JP16231595A patent/JP3650166B2/ja not_active Expired - Fee Related
- 1995-06-28 CN CN95193821A patent/CN1151696A/zh active Pending
-
1996
- 1996-12-27 KR KR1019960707507A patent/KR970703764A/ko not_active Application Discontinuation
- 1996-12-27 NO NO965605A patent/NO965605L/no not_active Application Discontinuation
- 1996-12-27 FI FI965230A patent/FI965230A/fi not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05339224A (ja) * | 1992-06-10 | 1993-12-21 | Tokuyama Soda Co Ltd | シアノケトン誘導体の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP3650166B2 (ja) | 2005-05-18 |
CN1151696A (zh) | 1997-06-11 |
KR970703764A (ko) | 1997-08-09 |
EP0761215A4 (en) | 1998-08-05 |
FI965230A0 (fi) | 1996-12-27 |
MX9700045A (es) | 1997-04-30 |
EP0768085A1 (en) | 1997-04-16 |
CA2193865A1 (en) | 1996-01-11 |
JPH08333251A (ja) | 1996-12-17 |
FI965230A (fi) | 1996-12-27 |
WO1996000570A1 (fr) | 1996-01-11 |
EP0761215A1 (en) | 1997-03-12 |
AU2806495A (en) | 1996-01-25 |
NO965605L (no) | 1997-02-24 |
NO965605D0 (no) | 1996-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4065563A (en) | 3-Hetero-5-isothiocyanophenyl oxadiazoles as antifungal and antibacterial agents | |
JP4955171B2 (ja) | 抗炎症剤としての尿素誘導体 | |
DK172077B1 (da) | 6-Fluor-7-(4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinolin-3-carboxylsyre-derivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende disse forbindelser | |
FR2555584A1 (fr) | Derives de l'acide fluoro-6-dihydro-1,4-oxo-4-piperazinyl substitue-7-quinoline-carboxylique-3 et procede pour leur preparation et compositions pharmaceutiques a action anti-bacteriennes a base desdits derives | |
JP2017533187A (ja) | 非β−ラクタム系抗生物質 | |
US4559342A (en) | Quinolone acids and antibacterial agents containing these compounds | |
HU198471B (en) | Process for producing quinolinecarboxylic acid derivatives and pharmaceutical compositions comprising these compounds as active ingredient | |
AU582214B2 (en) | Anthelmintic pyridinyl acylhydrazones, method of use and compositions | |
JP2019520317A (ja) | ベンゾイルグリシン誘導体およびその作製および使用の方法 | |
TW201305126A (zh) | 連續芳環化合物 | |
KR20190115451A (ko) | 항-섬유성 화합물 | |
JPH05117268A (ja) | ピリジン化合物 | |
JP2006503837A (ja) | 新規の抗マイコバクテリア化合物 | |
WO1996000571A1 (fr) | Agent antibacterien | |
FR2867472A1 (fr) | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0178388A1 (en) | Quinolinecarboxylic acid derivatives | |
JPS59112978A (ja) | プロピニルアミノチアゾ−ル誘導体 | |
JP3670292B2 (ja) | ケトニトリル誘導体及びこれを含有する抗菌剤及び医薬 | |
US4044130A (en) | Compositions for the control of microorganisms | |
CN107531613B (zh) | 苯并脂肪环取代烷基胺类化合物及其用途 | |
CN101547906A (zh) | 抗菌喹啉衍生物 | |
EP0221541A2 (en) | Quinolonecarboxylic acid derivatives and their preparation | |
EP0216323A2 (en) | Quinolonecarboxylic acid derivatives and their preparation | |
JPS60260577A (ja) | 1,8−ナフチリジン誘導体 | |
JPS60500372A (ja) | ハロゲノベンゾフエノン−オキシム誘導体系の新薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): DE FR GB |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995923538 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2193865 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1996 750855 Country of ref document: US Date of ref document: 19961229 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1995923538 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995923538 Country of ref document: EP |